Not known

Serious adverse reactions related to the injection procedure ocuring is less than 1%
which ncluded endophthalmitus, retinal  detachment, and intragoenic traumatic cataract

Most frequently reported adverse reactions- in approx ( 10 to 30% )
anterior chamber inflamation, blurred vision, cataract, conjuntival hemorrhage, corneal edema,
eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure,
ocular discomfort, reduced visual acuity, visual disturbances., visual floaters, and vitreous
opacites.

Ocular or periocularinfections , known hypersensitivity to pegaptanib or other component

Special Precautions/Warnings-

Renal function impairment - dosage adjustment for patients with renal failure is not required when administering 0.3mg dose

Endophthalmitis - intravenous injections including those with pegaptanib have been associated with endophthalmitis . Use proper asceptic injection technique when administering pegaptanib. In addition monitor patients during the week following injection to permit early treatment if required

Increased intraocular pressure- icrease in intraocular pressure have been seen within 30 minutes of injection with pegaptanib. Monitor and manage intraocular pressure.

Administration - for ophthalmic intravitreal injection only.

Pregnancy - use of pragaptanib during pregnancy only if the potential benefit to mother  justifies the potential risk to the fetus.

Lactation- excercise caution when peganaptib is administered to a breast feeding woman

Children- safety and efficacy of use in children have not been established

Monitoring- following injection, monitor patient for elevation of intraocular pressure and for
endophthalmitis. Insruct patients to report sysptoms suggestive of endophthmitis

Indication-

Neovascular age-related macular degeneration ( AMD )

Dosage-
The injection procedure should be carried out under controlled aspectic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyellid speculum

The patients medical history of hypersensitivity reactions should be evaluated prior to
performing intravitreal  procedure. Adequate anesthesia and a broad spectrum microcide
should be given prior to injection

1. In the days following pagaptanib administration patients are at risk for the development of
 endophthalmitis .

2.  If eye becomes red, sensitive to light , painful, or develops a change of vision,   the patient should seek immediate attention of an  ophthalmologist

Pregnancy -
Use of pragaptinib during pregnancy only if the potential benefit to mother  justifies
the potential risk to the fetus.

Lactation-
Excercise cautionwhen peganaptib is administered to a breast feeding woman

Children-
Safety and efficacy of use in children have not been established